Massive Genomic Study of 2.2 Million People Traces Addiction Risk to Brain Wiring and Impulse Control Genes

A Rutgers-led study of 2.2 million people finds that genetic addiction risk is rooted in brain wiring and impulse control rather than specific substances.

By: AXL Media

Published: Mar 20, 2026, 8:38 AM EDT

Source: The information in this article was sourced from Rutgers University

The Neurological Foundation of Behavioral Disinhibition

A comprehensive genetic study totaling more than 2.2 million individuals has fundamentally reframed our understanding of addiction as a product of neural architecture. Led by Holly Poore of the Rutgers Robert Wood Johnson Medical School, the research suggests that the majority of genetic risk for developing a substance use disorder (SUD) originates from genes that regulate how the brain processes rewards and weighs consequences. This "behavioral disinhibition" pathway is a heritable pattern that transcends specific substances, linking addiction risk to other externalizing traits such as impulsivity, ADHD, and conduct problems.

Teasing Apart Global and Substance-Specific Pathways

The study, published in Nature Mental Health, utilized advanced genomic methods to differentiate between two primary tracks of vulnerability. While the broad pathway involves brain signaling and neural plasticity, the researchers also identified substance-specific signals. For instance, while one set of genes may make an individual generally more prone to risky behavior, a secondary layer of genetic variants might specifically influence alcohol metabolism or nicotine receptors. This discovery marks the first time science has successfully teased apart these overlapping biological influences at such a massive genomic scale.

Predictive Power of Polygenic Risk Scores

By analyzing data across alcohol, tobacco, cannabis, and opioid use disorders simultaneously, the Rutgers-led team developed more robust polygenic scores. These summary measures combine thousands of genetic variants into a single index of liability, allowing clinicians to think about risk on two distinct levels. A broad metric can identify individuals generally vulnerable to a range of externalizing problems, while substance-specific scores provide a more granular look at risks associated with a particular drug. Senior author Danielle Dick emphasized that while these scores do not determine destiny, they are vital for identifying candidates for targeted prevention and early intervention.